Labiotech.eu’s Post

10 Noteworthy Global Biotech Companies that Got Funded in the first Quarter of 2024 According to data sourced from Crunchbase, the funding for Biotech companies represents a 161 percent upsurge compared to the USD 1.1 billion raised by the largest funding rounds which involved healthcare-focused biotech companies in the first quarter of 2023. Read the full article: https://goo.su/HCqWR By Samrat Pradhan, Managing Editor, #FinanceOutlookIndia Zephyr AI Yiyuan Yin FogPharma Mike Nolan Andrew Chi Baiteng Zhao Tubulis GmbH Laura Shawver Rakuten Medical Clasp Therapeutics Greg Chow, Freenome Diagonal Therapeutics Jixing Pharmaceuticals Obsidian Therapeutics Alamar Biosciences, Inc. ARS Pharmaceuticals, Inc. Nadia Agopyan, Ph.D., RAC Mark M, Sionna Therapeutics BlossomHill Therapeutics, Inc. BJ Sullivan, PhD, BioAge Labs Catherine Priest, Neurona Therapeutics #GlobalBiotech #FirstQuarter2024 #Biotechnologyindustry #FundingRounds #EmergingBiotechFirms #VentureCapital #TechnologicalAdvances #InnovationSpotlight

It’s time to find out who bagged the biggest private biotech investments in June 2024! 💰 The biggest funding rounds went to the companies Formation Bio, ITM Isotope Technologies Munich SE, and Marea Therapeutics. 📈 Meanwhile, around the world, oncology and central nervous system players attracted the biggest funding rounds overall. 🌍 Read our latest article to find out more about biotech’s biggest private investments in June, as we break down the investments by location and funding type, and compare June’s fundraising to previous months. 💡 https://lnkd.in/dYvuBVt9 #biotechinvestments #oncologyresearch #biotechfunding #healthcareinnovation #investmenttrends #globalbiotech #lifesciences Santa Ana Bio, Inc. | Alzheon, Inc. | Preserving Future Memories | Bright Peak Therapeutics | iOnctura | InduPro | Exsilio Therapeutics | Elion Therapeutics | Enveda Biosciences | Iambic Therapeutics | Spur Therapeutics | āshibio, Inc | Adcytherix | Envisagenics | Vilya | Frontier Medicines | Augustine Therapeutics | GPN Vaccines

Stories making headlines today in the biopharma industry: Acorda Therapeutics, a renowned biotech company, has declared bankruptcy amidst legal and financial difficulties since 2017. The company has decided to sell off its assets, including a proprietary Multiple Sclerosis drug, to Merz Therapeutics for a sum of $185 million. In other sector news, Roivant has shared uplifting results from their Phase 2 eye disease drug trial, conducted in partnership with pharmaceutical giant Pfizer. Capitalizing on this success, Roivant is launching an unprecedented $1.5 billion share buyback program. However, contrasting fortunes struck Gritstone as its Phase 2 study for a novel cancer vaccine delivered mixed results, leading to a significant drop in its stock value. Despite the recent upset, Gritstone remains optimistic and is committed to moving forward with public stock offerings and advanced Phase 3 trials. Meanwhile, Praia Health, a healthcare startup pioneering in improving patient engagement with healthcare systems, managed to secure $20 million in a recent Series A funding round. The promising venture seeks to leverage this substantial capital influx to develop groundbreaking products that seamlessly connect consumers with vital healthcare services. In the corporate world, Zymeworks revealed the removal of CFO Christopher Astle, with CEO Kenneth Galbraith set to fill the position on a temporary basis. Concurrently, Gilead confirmed the expansion of its existing deal with Nurix. Lastly, Verve Therapeutics has decided to hit pause on its leading gene editing program following an adverse safety event. In its pursuit of safety and proficiency, the firm plans to shift gears towards a similar program that employs a different type of lipid delivery mechanism. #pharma #biotech #topstories #biodatastudio

Merger & Acquisition Life Science / Healthcare 2023 Landscape Review Already this year we’ve seen Sanofi enter an agreement to acquire all outstanding shares of Inhibrx, Inc., as well as Johnson & Johnson’s recent acquisition of Ambrx Biopharma. 🔍 A quick review of Beacon Deals & Companies showed we identified 86 M&A deals last year 🔍 So, here’s one from every month … 🤝December: Bristol Myers Squibb Announced Definitive Merger Agreement to Acquire RayzeBio 🤝November: Selecta Biosciences Announces Merger with Cartesian Therapeutics 🤝October: Kyowa Kirin, Inc.- U.S. to Acquire Orchard Therapeutics 🤝September: Renovaro Biosciences Inc. and GEDiCube Sign Definitive Agreement to Combine 🤝August: Serina Therapeutics, Inc. and AgeX Therapeutics, Inc. Enter into Merger Agreement 🤝July: Biogen to Acquire Reata Pharmaceuticals, Inc. 🤝June: Talaris Therapeutics and Tourmaline Bio Entered into Merger Agreement 🤝May: Pyxis Oncology to Acquire Apexigen 🤝April: NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV 🤝March: Flamingo Therapeutics Signed a Definitive Merger Agreement with Dynacure 🤝February: Kite Pharma Completed the Acquisition of Tmunity Therapeutics Incorporated 🤝January: Leap Therapeutics Acquires Flame Biosciences If you’re interested in learning more about how Beacon tracks the company and deal data in the Cell Therapy, Gene Therapy, RNA, ADC, Bispecific, Immune Tolerance, Checkpoint, Cytokine, DDR, TPD, Microbiome, Cancer Vaccine, or Oncolytic Virus landscapes drop me a message. #drugdevelopment #pharma #MnA #biotech

UNP Scores $32M for AI-Powered Macrocycle Therapeutics - HIT Consultant #UNP Scores $32M for AI-Powered Macrocycle Therapeutics #Summary: UNP, a healthcare technology company, has raised $32 million in funding for its AI-powered macrocycle therapeutics. The company aims to develop novel treatments for diseases that are currently difficult to treat. The funding will be used to advance the company's drug discovery platform and accelerate the development of its pipeline. UNP's technology combines artificial intelligence and machine learning to design and optimize macrocycles, which are large, complex molecules that can interact with disease targets. The company's approach has the potential to revolutionize drug discovery and lead to the development of more effective therapies. #Introduction: UNP, a healthcare technology company, has secured $32 million in funding ai.mediformatica.com #platform #funding #oncology #biotech #design #globalhealth #health #healthinnovation #innovation #medical #merckglobalhealthinnovationfund #seriesa #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3tp5PyH)

There's been some really exciting news for Nimbus Therapeutics today as they closed a $210 million private investment round, led by GV (Google Ventures), SR One Capital Management and Atlas Venture. This investment round, while already being one of the biggest of 2023, follow up on a sale of Nimbus' experimental autoimmune medicine to Takeda for a massive $6 billion earlier this year and a previous investment round of $125m last September. To date, Nimbus have raised a huge $427m. Nimbus focuses on developing novel therapies for treatment of cancer, inflammatory and autoimmune conditions and metabolic diseases using small molecule. They utilise some unique technologies to develop these therapies, including machine learning-based predictive modeling approaches. Follow Warman O'Brien for all the latest news in the Life Sciences industry! #clinicalresearch #pharmaceutical #biotechnology #goodnews

🔬Messaginglab and Degron Therapeutics Partnered on a $1.2B Collaboration Announcement - With Big Results 🧬 We're thrilled to have collaborated with Degron Therapeutics - an emerging leader in the discovery of small molecule, molecular glue degrader drugs - on their recent press release announcing their $1.2B collaboration with Takeda. Molecular glue degraders are small molecule drugs that act as adhesives by bringing a disease target protein to another protein called E3 ligase, which is a component of a protein degradation machinery. As a result, the disease target protein is “tagged” as trash and degraded in the cell.   This approach has the potential to target previously undruggable proteins, opening new avenues for treating challenging diseases in cancer, inflammation, neurodegenerative and other disorders. Messaginglab's Impact: 💡Translating Difficult Science: We simplified the complexity of molecular glues to help Degron reach a broader audience. Our approach resonated widely for investors, partners, and the public. 💡Amplifying Media Presence: Through targeted outreach, we secured coverage in 20 top life science and pharma publications, including Biocentury, BioWorld, Chemical & Engineering News, and Fierce Biotech. This expanded visibility positioned Degron as a key player in biotech. 💡Crafting a Compelling Corporate Narrative: Beyond the $1.2B deal, we highlighted Degron's mission to revolutionize drug discovery. We created an emotional connection by focusing on the impact on patients' lives, elevating Degron's story above financial metrics. 💡Showcasing Thought Leadership: We positioned Degron's co-founder and CEO, Lily Zou, as a visionary leader. Her quotes and media accessibility added a human touch to the company's technological breakthroughs, building trust and credibility. 💡Driving Meaningful Engagement: Our success went beyond metrics. We focused on generating high-quality media coverage that sparked conversations among key stakeholders in the biotech community. The Power of Partnership: We're proud to have been a part of this groundbreaking work. Our collaboration with Degron Therapeutics showcases Messaginglab's ability to elevate complex science through strategic communication. #MediaRelations #BiopharmaNews

Stories making headlines today in the biopharma industry: Merck's CMO, Eliav Barr, has declared the organization's intention to magnify its immunology pipeline through further deals, specifically focusing on cardiometabolic drugs and immunology. In other news, GSK has pledged to purchase Aiolos Bio, a clinical-stage asthma drugmaker, for a hefty $1.4 billion. This development has facilitated one of the swiftest startup reveal-to-acquisition journeys in biotech history, as Aiolos Bio was only unveiled three months ago, bolstered by the backing of a number of renowned investors. Meanwhile, rumors indicating a possible acquisition of the biotechnology company Cytokinetics by Novartis have been downplayed by the latter's CEO, Vas Narasimhan. In an interview with CNBC, he emphasized Novartis' focus on smaller, "$5 billion or less" assets, debunking the alleged buyout speculation. On another note, radiopharma firm Lantheus has initiated collaboration with Perspective Therapeutics, investing $28M upfront to secure an exclusive licensing deal directed towards an alpha-targeted therapy for neuroendocrine tumors. This move is set to extend its hand even further in the radiopharma sphere and solidify its presence in this field. #pharma #biotech #topstories #biodatastudio

Gene&Cell Therapy >> Attovia reels in $105M from crossover investors to run multiple trials of I&I biologics: California biotech Attovia Therapeutics is back with a $105 million Series B just 11 months after unveiling with $60 million. The Fremont-based startup eyes a series of clinical trials in the crowded inflammation and immunology field with the new money. It will enter human studies in the coming months for its lead program in atopic dermatitis and bring a second biologic into the clinic next year. Overall, the money will bankroll the first two assets through Phase 1 and into Phase 2, as well as take a third discovery program into the clinic, CEO Tao Fu told Endpoints News. Fu highlighted the “crossover” profile of investors in its Goldman Sachs-led Series B, which gives Attovia “flexibility” in determining whether the public markets are its next step. While the IPO window is still largely shut, the drumbeat of large, nine-figure financings has been almost endless so far in 2024. Attovia’s financing, revealed Thursday morning, represents the 37th such megaround disclosed by a drug developer so far this year, according to an Endpoints tally. Entering a crowded space Born out of precision proteomics company Alamar Biosciences, Attovia will largely focus on inflammation and immunology, or I&I, an area of biopharma R&D that has picked up steam thanks to some high-profile acquisitions and a string of approvals. In the lead at Attovia is ATTO-1310, an anti-IL-31 biologic that the biotech will test for eczema and other pruritic diseases. The FDA and European Medicines Agency are both currently reviewing an approval application for an IL-31 inhibitor. Those regulators, and ones in four other countries, are also reviewing Galderma’s anti-IL-31 monoclonal antibody nemolizumab for both prurigo nodularis and atopic dermatitis. The dermatology company, which went public earlier this year, licensed the asset from Chugai Pharmaceutical in 2016. Attovia hopes to create a less frequent treatment option. Galderma’s was delivered every four weeks in clinical trials. Attovia believes ATTO-1310, also an under-the-skin treatment, can be dosed every three months based on non-human primate data, Fu said. The biotech thinks it can do so with biparatopic nanobodies. Its molecule binds to two sites on the same protein targets, which Attovia believes will get the antibody to bind more tightly to the target and lead to greater specificity. Even if one arm falls off, the other will still be clinging on. The biotech’s second program, named ATTO-002, goes after both IL-31 and IL-13. “We basically built two best-in-class single binders into one molecule,” Fu said. Attovia will choose a development candidate in the second half of this year and file an IND next year, it said. It will explore undisclosed immune-mediated diseases. Sanofi… #lucidquest #genetherapy #celltherapy

Biotech funding is the financial backing of biotechnology research and development, usually through private investors or venture capital firms. Some notable biotech funding deals in recent months include ¹: - Recent biotech pre-seed funding: - NXI Therapeutics (Switzerland): $3.96 million, for immunotherapies - Recent biotech seed funding: - Advesya (France): $23 million, for cancer therapies - Cumulus Oncology (United Kingdom): $11.45 million, for cancer drug discovery - DISCO Pharmaceuticals (Germany): $21.75 million, for drug discovery - Recent biotech series A funding: - Claris Bio (United States): $57 million, for corneal therapies - Resalis Therapeutics (Italy): $10.95 million, for non-coded RNA-based therapeutics - OnCusp Therapeutics (United States): $100 million, for oncology assets - Recent biotech series B funding: - Vico Therapeutics (Netherlands): $60 million, for RNA modulation - Full-Life Technologies (China, Belgium): $47.3 million, for radionuclide drug conjugates - Avistone Biotechnology (China): $140 million, for targeted cancer drugs #biotech #funding #venturecapital #investing #biotechnology #lifesciences #healthcare #innovation #startups #biotechnews #pharmaceuticals #medtech #biotechindustry #investmentnews #fundingnews #biotechcompanies #biotechinvesting